echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The current situation and trends of ai-drug research and development market are discussed.

    The current situation and trends of ai-drug research and development market are discussed.

    • Last Update: 2020-09-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    A new drug from idea out to commercial sales, need to go through drug discovery, preclinical research, clinical research and approval of the market four stages, so the new drug research and development has a long research and development cycle, high research and development costs, research and development risk of the three pain points, artificial intelligence can be applied to drug research and development in a number of scenarios, to help improve the efficiency and success rate of new drug research and development.
    , China's AI-drug research and development is still in its infancy, and the development is still facing many challenges.
    1, AI energy-enabled drug research and development nine scenarios Artificial intelligence technology can be used in drug discovery, preclinical research, clinical trials, drug production and marketing promotion five stages, mainly used in target discovery, compound synthesis, new adaptive findings, compound screening, crystal prediction, patient recruitment, optimization of clinical trial design, drug examination, academic promotion and other nine scenarios.
    to improve the efficiency of drug development, production and marketing by utilizing AI technologies such as natural language processing, deep learning, machine learning, and image recognition.
    Figure 1: The application scenario of AI-plus drug research and development At present, AI is mainly used in the drug discovery stage and pre-clinical research stage, in which target discovery is the most popular field of AI-plus drug research and development, according to the development rate of the application scenario, the future drug synthesis may become the most automated direction.
    in the production and marketing of pharmaceutical products is in the initial exploration stage, such as AstraZenecon's Wuxi supply base in China, the application of AI to the packaging line of product inspection.
    In the direction of academic promotion exploration, Firestone to create doctor's sales before the new drug market, patient disease drug information transmission, county market coverage, intelligent medical robots will subvert the traditional medicine on behalf of medical content communication and transmission, to achieve accurate value transmission of medical information.
    Table 1: Overview of the Application of AI Technology in Drug Development Note: Pilot Compound Research refers to the combination of millions of small molecule compounds to discover compounds with a certain biological activity and chemical structure, generally with two ideas, namely high-volume screening and virtual drug screening.
    II, AI plus drug research and development market three main IT giants, AI plus drug research and development innovation enterprises, large pharmaceutical enterprises At present, AI plus drug research and development market has three categories of companies, IT giants, AI plus drug research and development innovation enterprises and large pharmaceutical enterprises.
    IT giants tend to use their Internet foundation and platform advantages for technology layout, access to independent research and development of related products, the development of related areas of targeted technology enabling industry applications, business areas continue to sink, or through extended mergers and acquisitions to expand the business map, such as Tencent into AI drug research and development, the launch of the first AI-driven drug discovery platform "iDrug."
    Figure 2: AI-Drug Research and Development Enterprise Map AI-Drug Research and Development Enterprises cut into one or more application scenarios with technical advantages, while large pharmaceutical companies lay out AI drug research and development in a way that forms their own technical teams or cooperates with AI technology companies.
    lack of data on drug development, proven research and development pipelines, and experienced drug experts at AI-Plus Drug Research and Development Innovations, which happens to be an advantage for traditional pharmaceutical giants.
    this, large pharmaceutical companies and AI-drug research technology companies are currently the main business models, such as Pfizer and Jingtai Technology in cooperation with drug crystal prediction and screening.
    table 2: Large pharmaceutical companies and AI start-ups cooperation case Source: Firestone creation according to public information finishing three, China's AI drug research and development major enterprises and business layout According to CB Insights statistics, there are currently 138 AI-drug research and development start-ups worldwide, the United States has 86, the largest number, followed by the United Kingdom and Canada, Israel, Japan, South Korea also have business distribution.
    China's AI drug research and development started late, is still in the initial stage, according to firestone database data show that China's AI-drug research and development start-ups less than 20, the emergence of Jingtai Technology, Deep Zhiyao, Cloud Potential Software, Wangshi Wisdom and other innovative enterprises, mainly in Beijing (7), Shanghai (3), Hangzhou (3) and Shenzhen (2) and other places, from the enterprise business layout, drug discovery is China's most popular areas of AI-drug research and development.
    Figure 3: The business layout of China's main AI-drug research and development companies Source: Firestone Creation according to public information finishing four, AI drug research and development needs to solve the problem of one is that the business model is not clear.
    enterprises need a reasonable positioning role, choose the right business model.
    currently, AI drug research and development is really less of a output, and in April 2019, IBM decided to stop developing and selling Watson's artificial intelligence suite, a drug development tool, because of poor financial performance.
    most enterprise development depends on financing, for AI-drug research and development technology innovation enterprises, is to do their own drug research and development or CRO model, is the need to combine their own development to make suitable choices.
    is the lack of high-end composite talent.
    AI drug research and development both information technology and medicine dual attributes, both need AI talent and understand drug research and development personnel, need to train a number of cross-disciplinary composite talent team.
    third is data constraints.
    AI training model needs high-quality data, new drug research and development data is basically in the hands of pharmaceutical companies, open data is relatively limited, so how to obtain high-quality data, the establishment of research and development data standard system to improve the data are AI-drug research and development start-ups face difficulties.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.